Cited by 1,296HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Open access

Marrazzo, Jeanne M., Ramjee, Gita, Richardson, Barbra A., Gomez, Kailazarid, Mgodi, Nyaradzo, Nair, Gonasagrie, Palanee, Thesla, Nakabiito, Clemensia, van der Straten, Ariane, Noguchi, Lisa, Hendrix, Craig W., Dai, James Y., Ganesh, Shayhana, Mkhize, Baningi, Taljaard, Marthinette, Parikh, Urvi M., Piper, Jeanna, Mâsse, Benoît, Grossman, Cynthia, Rooney, James, Schwartz, Jill L., Watts, Heather, Marzinke, Mark A., Hillier, Sharon L., McGowan, Ian M., Chirenje, Z. Mike·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1402269PMC PMC4341965

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1402269

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647

Show all 19 references

Sorted by citations

Items 901–999 of 999

Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research
Velloza, J., Roche, S. D., Concepcion, T. L., & Ortblad, K. F. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000768 · Cited by 6
Sexual Practices and Predisposition to PrEP Use Among Men Ages 50 Years and Older Who Have Sex With Men: A Cross-Sectional Study
Nunes, R. V., de Araújo, T. M. E., de Oliveira, L. B., Almeida, P. D., Lima, S. V. M. A., Magalhães, R. D. L. B., Valle, A. R. M. D. C., Fronteira, I., Mendes, I. A. C., & de Sousa, Á. F. L. (2023) · Journal of the Association of Nurses in AIDS Care · doi:10.1097/jnc.0000000000000433 · Cited by 5
Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study
Wynne, J., Muwawu, R., Mubiru, M., Kamira, B., Kemigisha, D., Nakyanzi, T., Kabwigu, S., Nakabiito, C., & Matovu, F. (2018) · HIV Clinical Trials · doi:10.1080/15284336.2018.1513711 · Cited by 7
Correlates of Sexually Transmitted Infections Among South African Women Using Individual- and Community-Level Factors: Results from Generalized Additive Mixed Models
Wand, H. C., Morris, N., Dassaye, R., Reddy, T., & Gita Ramjee, H. (2019) · Archives of Sexual Behavior · doi:10.1007/s10508-018-1315-3 · Cited by 5
Factors associated with knowledge of pre-exposure prophylaxis in pregnant women in Cape Town, South Africa
DiTullio, D. J., Farley, E., Gomba, Y., Coates, T. J., Bekker, L., Myer, L., & Davey, D. J. (2019) · International Journal of STD & AIDS · doi:10.1177/0956462419863216 · Cited by 5
VOICE reveals the need to improve adherence in PrEP trials
Tobin, S. C. (2015) · AIDS · doi:10.1097/qad.0000000000000693 · Cited by 5
A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds
Hope, T. J., & Marrazzo, J. M. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0310 · Cited by 5
Blocking HIV‐1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses
Eid, S. G., Mangan, N. E., Hertzog, P. J., & Mak, J. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.23 · Cited by 5
Innovative sensory methods to access acceptability of mixed polymer semisoft ovules for microbicide applications
Zaveri, T. D., Running, C. A., Surapaneni, L., Ziegler, G. R., & Hayes, J. E. (2016) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0309-8 · Cited by 5
Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol
Price, J. T., Mollan, K. R., Fuseini, N. M., Freeman, B. L., Mulenga, H. B., Corbett, A., Vwalika, B., & Stringer, J. S. A. (2017) · Pilot and Feasibility Studies · doi:10.1186/s40814-017-0170-7 · Cited by 5
PrEParing for the Unexpected: Mechanisms and Management of HIV pre-exposure Prophylaxis Failure
Dashwood, T., & Tan, D. H. S. (2018) · Future Virology · doi:10.2217/fvl-2018-0084 · Cited by 5
Methods for Assessing the Adherence to Medical Devices
Johnson, L. M., Swarner, S., van der Straten, A., & Rothrock, G. D. (2016) · doi:10.3768/rtipress.2016.mr.0036.1610 · Cited by 5
Psychological and Behavioural Within-participant Predictors of Adherence to Oral HIV Pre-Exposure Prophylaxis (PrEP)
Taylor, A., Hayes, R., Nwokolo, N. C., Whitlock, G. G., Dosekun, O., McCormack, S., Gafos, M., & Evangeli, M. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04151-8 · Cited by 4
Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence
Husnik, M. J., Heffron, R. A., Hughes, J. P., Richardson, B. A., van der Straten, A., Palanee‐Phillips, T., Soto-Torres, L. E., Singh, D., Mirembe, B. G., Livant, E., et al. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04463-3 · Cited by 4
Indirect Treatment Comparison of Long-Acting Injectable Cabotegravir as Pre-exposure Prophylaxis When Compared with no Pre-exposure Prophylaxis for HIV Prevention
Hawkins, N., O’Brien, P. D., Thompson, J. C., Anderson, S., Manalastas, E. J., Benjamin, L., & Schroeder, M. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01172-9 · Cited by 4
Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis ( PrEP ) Against HIV
Kim, H. Y., Liebenberg, A., Zhang, L., & von Kleist, M. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70254 · Cited by 4
Brief Report: Genital Microbiome, Inflammation, and Tenofovir Levels in Transgender Men and Cisgender Women Taking Oral PrEP
Hastie, E., Srivatsa, M. S., Gianella, S., Cottrell, M. L., Forsyth, K., Porrachia, M., Burke, L., Morris, S., Rawlings, S. A., Karris, M., et al. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003521 · Cited by 4
Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS
Montaner, J. S. G., Lima, V. D., Salters, K. A., Toy, J., Joy, J. B., Guillemi, S. A., & Barrios, R. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10030075 · Cited by 4
Understanding PrEP misconceptions and their impact on PrEP initiation and use among pregnant and lactating women in Malawi
Nyamaizi, A. M., Catlett, M., Saidi, F., Phanga, T., Tseka, J., Bula, A. K., Pearce, L. D., Maman, S., Golin, C. E., Mutale, W., et al. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004667 · Cited by 4
Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis
van de Vijver, D. A. M. C., Mukherjee, S., & van Kampen, J. J. A. (2021) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-021-00246-9 · Cited by 4
Awareness, knowledge and comfort of pharmacy students on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV prevention
Bhuiyan, J., Bradley, N. E., Lee, Y., & Conry, J. M. (2021) · Pharmacy Education · doi:10.46542/pe.2021.211.517527 · Cited by 5
Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya
Musinguzi, N., Ngure, K., Bukusi, E. A., Mugo, N., Baeten, J. M., Anderson, P. L., & Haberer, J. E. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04111-2 · Cited by 4
Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP
Kinsale, T. S., Cottrell, M. L., Li, L., Brand, R. M., Gatto, G., Luecke, E. H., Norton, C. A., Krovi, S. A., Dumond, J. B., Rao, G. G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020201 · Cited by 4
Phase 1 randomized pharmacokinetic and safety study of a 90‐day tenofovir vaginal ring in the United States
Liu, A., Gundacker, H. M., Richardson, B. A., Chen, B. A., Hoesley, C. J., van der Straten, A., Brown, A., Beamer, M. A., Robinson, J. A., Jacobson, C. E., et al. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26223 · Cited by 4
Generalizing the Intention-to-Treat Effect of an Active Control from Historical Placebo-Controlled Trials: A Case Study of the Efficacy of Daily Oral TDF/FTC in the HPTN 084 Study
He, Q., Gao, F., Dukes, O., Delany‐Moretlwe, S., & Zhang, B. (2024) · Journal of the American Statistical Association · doi:10.1080/01621459.2024.2360643 · Cited by 4
Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review
Wu, L., Niu, X., Brunelli, M. K., & Mugwanya, K. K. (2024) · Current HIV/AIDS Reports · doi:10.1007/s11904-024-00705-0 · Cited by 4
Prolonged release and antiviral efficacy of HIV fusion inhibitor LP-98-loaded microspheres in rhesus macaques
Cong, Z., Wei, Y., Chong, H., Zhang, D., Tong, L., Zhang, J., Zhu, Y., Gao, Z., Jin, H., Lu, J., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.018 · Cited by 5
The Leaky Preexposure Prophylaxis Cascade—Barriers and Facilitators to Preexposure Prophylaxis Uptake and Adherence Among Youth Experiencing Homelessness in the US South: A Mixed Methods Study
Maria, D. S., Paul, M. E., Lightfoot, M. A., Nyamathi, A., Quadri, Y., Padhye, N. S., Ocampo, E., Babayev, R., Ramos, M. W., Malone-Thomas, S., et al. (2024) · Journal of the Association of Nurses in AIDS Care · doi:10.1097/jnc.0000000000000516 · Cited by 4
Update on HIV Chemoprevention
Blair, C. S., Cambou, M. C., & Landovitz, R. J. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-042823-013707 · Cited by 4
User and healthcare provider early experiences with the PrEP ring: a quantitative study on the introduction of a new PrEP method in Eswatini
Hettema, A., Shongwe, S., Sisel, H., Khumalo, M., Gama, N., Khanyile, N., Mahlalela, B., Matse, S., & Peterson, J. (2025) · Journal of the International AIDS Society · doi:10.1002/jia2.26490 · Cited by 4
Contemporary HIV Vaccines: Tissue Resident T-Cells and Strategies to Prevent Mucosal Infection
Tan, H., Kent, S. J., & Rose, R. D. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150901114920 · Cited by 4
Time to Make the Jump: Translating HIV Pre-exposure Prophylaxis Research Into Real-World Public Health Impact
Patel, R. R., Chan, P. A., Mena, L. A., Crowley, J. S., McCoy, K., & Nunn, A. S. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001386 · Cited by 4
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial
Riddler, S. A., Husnik, M. J., Gita Ramjee, H., Premrajh, A., Tutshana, B. O., Pather, A., Siva, S. S., Jeenarain, N., Nair, G., Selepe, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178594 · Cited by 4
Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey
Stalter, R. M., Tharaldson, J., Owen, D. H., Okumu, E., Moench, T. R., Mack, N., Tolley, E. E., & MacQueen, K. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180963 · Cited by 4
Evaluation of the awareness, knowledge and use of pre-exposure prophylaxis (PrEP) among the serodiscordant partners of HIV infected individuals on ART in an urban HIV clinic
Ishiekwene, C., Thomas-Powell, S., Ghitan, M., Kuhn-Basti, M., Chapnick, E. K., & Lin, Y. S. (2018) · Cogent Medicine · doi:10.1080/2331205x.2018.1475124 · Cited by 4
Women and HIV in the Twenty-First Century: How Can We Reach the UN 2030 Goal?
O’Leary, A. (2018) · AIDS Education and Prevention · doi:10.1521/aeap.2018.30.3.213 · Cited by 4
Stakeholder acceptability of adolescent participation in clinical trials for biomedical HIV prevention products: considerations from Tanzania and India
Pack, A. P., Sastry, J., Tolley, E. E., Kaaya, S., Headley, J., Kaale, A., & Baumgartner, J. N. (2018) · AIDS Care · doi:10.1080/09540121.2018.1563285 · Cited by 4
Incorporating patient input into the design of a disease management program for COPD
Paradise, R. K., Dryden, E. M., Elvin, D., Fisher, C. J., Touw, S., Trumble, L., & Batalden, M. (2019) · Healthcare · doi:10.1016/j.hjdsi.2019.05.003 · Cited by 5
HIV and Immigrants from Sub-Saharan Africa and the Caribbean Living in the United States
Ojikutu, B. O., Nnaji, C., & Dévieux, J. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-48744-7_7 · Cited by 5
Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls
Baker, Z. G., Javanbakht, M., Moore, J., Brosnan, H. K., Squires, K., Bunge, K. E., Zimet, G. D., Mensch, B., Soto-Torres, L. E., Kapogiannis, B. G., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002674 · Cited by 4
Effect of a storytelling intervention on the retention of serodiscordant couples in ART/PrEP services at antenatal clinic in Namacurra province in Zambézia, Mozambique
Audet, C. M., Graves, E., Emílio, A. M., Matino, A., Paulo, P., Aboobacar, A., Fonseca, C. L., Rompaey, S. V., & Schacht, C. D. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100782 · Cited by 4
Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide
Johnson, K. A., Okochi, H., Glidden, D. V., Gandhi, M., & Spinelli, M. A. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002727 · Cited by 4
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated
Tessema, F. A., Barenie, R. E., Avorn, J., & Kesselheim, A. S. (2023) · Health Affairs · doi:10.1377/hlthaff.2022.01134 · Cited by 4
Cell-Penetrating Drug Carrier by Molecular Recognition of Sphingomyelin on Plasma Membranes
Cheng, X., Miao, Y., Zhou, J., Lu, F., Jin, J., & Hu, L. (2024) · Langmuir · doi:10.1021/acs.langmuir.4c00101 · Cited by 4
The science of Durban, AIDS 2016
Beyrer, C., Shisana, O., Baral, S., Milsana, K., Mayer, K. H., Pozniak, A., Walker, B. D., Mboup, S., Sohn, A. H., Serwadda, D., et al. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21781 · Cited by 4
El papel de las intervenciones biomédicas en la prevención del VIH: la profilaxis preexposición (PrEP)
Zioga, E., de la Torre, J. A., Patera, E., Borjabad, B., Macorigh, L., & Ferrer, L. (2019) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2019.06.006 · Cited by 4
HIV control strategies for sex worker–client contact networks
Mulberry, N., Rutherford, A. R., Wittenberg, R. W., & Williams, B. G. (2019) · Journal of The Royal Society Interface · doi:10.1098/rsif.2019.0497 · Cited by 4
Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women
Tarleton, J., Chen, B. A., Meyn, L. A., Hendrix, C. W., Marzinke, M. A., & Achilles, S. L. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002421 · Cited by 4
Evaluating family physicians’ willingness to prescribe PrEP
Villeneuve, F., Cabot, J.-M., Eymard‐Duvernay, S., Visier, L., Tribout, V., Perrollaz, C., Reynes, J., & Makinson, A. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.02.003 · Cited by 4
Acceptability of a trial of vaginal progesterone for the prevention of preterm birth among HIV-infected women in Lusaka, Zambia: A mixed methods study
Price, J. T., Mabula‐Bwalya, C. M., Freeman, B. L., Carda-Auten, J., Phiri, W. M., Chibwe, K. F., Kantumoya, P., Vwalika, B., Stringer, J. S. A., & Golin, C. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238748 · Cited by 4
Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention
Katz, A. W. K., Mansoor, L. E., Tsidya, M., Mathebula, F., Singh, D., Siva, S. S., Akello, C. A., Chitowa, T. H., Garcia, M., Soto-Torres, L. E., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03338-1 · Cited by 4
Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro
Mosher, E. P., Eberhard, C. D., & Bumpus, N. N. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.121.000348 · Cited by 4
Control groups for HIV prevention efficacy trials: what does the future hold?
Janes, H., & Buchbinder, S. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000818 · Cited by 4
Updates on Preventing HIV Infection
Choi, J. Y. (2016) · Korean Journal of Medicine · doi:10.3904/kjm.2016.90.6.474 · Cited by 4
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database
Rossotti, R., Borghi, V., Callegaro, A. P., Micheli, V., Bruzzone, B. M., Colao, G., Gismondo, M. R., Vicenti, I., Penco, G., Zazzi, M., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.08.293 · Cited by 4
Pregnant women’s attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy
Catallozzi, M., Fraiz, L. D., Hargreaves, K. M., Zimet, G. D., Stanberry, L. R., Ratner, A. J., Gelber, S. E., & Rosenthal, S. L. (2016) · International Journal of STD & AIDS · doi:10.1177/0956462416679067 · Cited by 4
Temporal trends in sexual behaviours and their impacts on HIV incidence among South African women: 2002–2016
Wand, H. C., Reddy, T., & Gita Ramjee, H. (2020) · AIDS Care · doi:10.1080/09540121.2020.1789054 · Cited by 4
Pre-Exposure Prophylaxis (PrEP) Adherence Questionnaire: Psychometric Validation among Sexually Transmitted Infection Patients in China
Yu, X., Xu, C., Ni, Y., Chang, R., Wang, H., Gong, R., Wang, Y., Wang, S., & Cai, Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010980 · Cited by 4
Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection
Arya, V., Au, S., Belew, Y., Miele, P., & Struble, K. A. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000163 · Cited by 4
CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention
Vanshylla, K., Held, K., Eser, T. M., Gruell, H., Kleipass, F., Stumpf, R., Jain, K., Weiland, D., Münch, J., Grüttner, B., et al. (2021) · Vaccines · doi:10.3390/vaccines9030198 · Cited by 4
Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection
Vermund, S. H., & Walker, A. S. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv336 · Cited by 4
Preventing HIV among Women — A Step Forward, but Much Farther to Go
Adimora, A. A. (2016) · New England Journal of Medicine · doi:10.1056/nejme1613661 · Cited by 4
CHARACTERIZING THE SAUTI vAGYW HIV RISK ASSESSMENT TOOL TO MEASURE VULNERABILITY OF ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA
Han, H. H. (2017) · Cited by 4
Extending access with long-acting antiretroviral therapy
Markowitz, M. H., & Meyers, K. A. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000167 · Cited by 4
Characterizing Cis and Trans Women’s HIV Risk and Access to HIV Prophylaxis in Ontario, Canada
Uum, R. V., Mashhadi, P. E., Canani, F., Masterman, C., Hirode, G., Bogoch, I. I., Gaete, K., Fisher, K. N., Jalali, Y., Rana, S., et al. (2025) · The Open AIDS Journal · doi:10.2174/0118746136387776250825202101 · Cited by 3
Demonstrating service delivery models for effective initiation and retention on pre-exposure prophylaxis (PrEP) among female bar workers in Dar es Salaam, Tanzania: A double randomized intervention study protocol
Chebet, J. J., Akyoo, W. O., Goymann, H., Harling, G., Barnhart, D. A., Mosha, I. H., Kamori, D., Gandhi, M., Mbunda, T. D., Kipeleka, J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304077 · Cited by 3
Medical chart-reported alcohol consumption, substance use, and mental health issues in association with HIV pre-exposure prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men
Shuper, P. A., Joharchi, N., Varatharajan, T., Bogoch, I. I., Loutfy, M. R., El‐Helou, P., Giolma, K., Woodward, K., & Rehm, J. T. (2024) · BMC Public Health · doi:10.1186/s12889-024-20934-7 · Cited by 3
Vaginally-delivered fast-dissolving antibody tablets (FDAT) for on-demand non-hormonal contraception and multi-purpose protection
Kushiro, K., Hammers, S., Zhu, Y., Flowers, H. B., Dawson, L. N., Panjwani, A., Schaefer, A., Quan, D., Gibb, K., McSweeney, M. D., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113662 · Cited by 3
Association between substance use and PrEP adherence among adolescent girls and young women enrolled in an HIV prevention study in Southern Africa
Hlahla, K., Choudhury, R. P., Siziba, B., Anderson, P. L., Delany‐Moretlwe, S., Ndzhukule, T. R., Hosek, S., Mgodi, N. M., & for the on behalf of the HPTN 082 Study Team (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004750 · Cited by 2
Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators
Upfold, M., Grobler, A. C., Suleman, F., & Mansoor, L. E. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1465-z · Cited by 3
Broad Neutralizing Antibodies to HIV Env and Other Complex Viral Antigens from Vaccinated Cows
Heydarchi, B., Salazar-Quiroz, N. A., & Purcell, D. F. J. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000347 · Cited by 2
Humoral responses against HIV in male genital tract
Gagneux‐Brunon, A., Rochereau, N., Botelho-Nevers, É., Lucht, F., Pozzetto, B., Paul, S., & Bourlet, T. (2017) · AIDS · doi:10.1097/qad.0000000000001460 · Cited by 3
Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises
Montjane, K., Dlamini, S. K., & Dandara, C. (2018) · South African Medical Journal · doi:10.7196/samj.2017.v108i2.13035 · Cited by 3
Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies
Aung, W. S., Bakshi, R. P., Breakey, J., Johnson, J. E., Hendrix, C. W., Weld, E. D., Fuchs, E. J., & Marzinke, M. A. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2211-5 · Cited by 3
Is Interview Length Associated With Blood Test Participation? Evidence From Three Population-Based HIV Impact Assessment Surveys Conducted From 2016 to 2017
Bray, R., Palma, A. M., Philip, N. M., Brown, K., Levin, B. L., Thompson, J. L. P., Ginindza, C., & Mulenga, L. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002705 · Cited by 3
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)
Mayer, K. H., Yuhas, K., Amico, K. R., Wilkin, T. J., Landovitz, R. J., Richardson, P., Marzinke, M. A., Hendrix, C. W., Eshleman, S. H., Cottle, L. M., et al. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03736-z · Cited by 3
Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria
Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S., Kotila, O. A., Berzins, B., Okochi, H., Tallerico, R., et al. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-022-00462-3 · Cited by 3
Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis
Garcia‐Cremades, M., Hendrix, C. W., Jayachandran, P., Strydom, N., Jarlsberg, L. G., Grant, R. M., Celum, C., Martin, M., Baeten, J. M., Marrazzo, J. M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091801 · Cited by 3
Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
Heron, J. E., McManus, H., Vickers, T., Ryan, K. E., Wright, E., Carter, A., Stoove, M. A., Asselin, J., Grulich, A. E., Donovan, B. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280339 · Cited by 3
Significant Publications on Infectious Diseases Pharmacotherapy in 2022
Teran, N. S., Buckley, V., Britt, R. S., Ikwuagwu, J. O., Thomas, J. L., Zaki, A., Olson, K., Stramel, S., & on behalf of the Houston Infectious Diseases Network (2023) · Journal of Pharmacy Practice · doi:10.1177/08971900231194200 · Cited by 3
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
Leung, E., Cottrell, M. L., Sykes, C., White, N., Kashuba, A. D. M., & Dumond, J. B. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13042 · Cited by 3
Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring
Stalter, R. M., Dong, T. Q., Hendrix, C. W., Palanee‐Phillips, T., van der Straten, A., Hillier, S. L., Kiweewa, F. M., Mgodi, N. M., Marzinke, M. A., Bekker, L., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad550 · Cited by 3
The effect of daily oral PrEP use during pregnancy on bone mineral density among adolescent girls and young women in Uganda
Zewdie, K., Kiweewa, F. M., Ssebuliba, T., Morrison, S. A., Muwonge, T. R., Boyer, J., Bambia, F., Badaru, J., Stein, G., Mugwanya, K. K., et al. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2023.1240990 · Cited by 3
Pre-Exposure Prophylaxis for HIV: Bioethical, Clinical, and Epidemiological Considerations
Markley, J. D. (2024) · The Linacre Quarterly · doi:10.1177/00243639241239068 · Cited by 3
Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials
Lorenzetti, L., Dinh, N., Whitcomb, C., Martínez, A., Chatani, M., Lievense, B., Nhamo, D., Slack, C. M., Eley, N. T., & MacQueen, K. M. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04459-z · Cited by 3
A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation
Devanathan, A. S., Poliseno, A., White, N., Schauer, A. P., Sykes, C., Weideman, A. M., Kilpatrick, K. W., Hudgens, M. G., Gay, C. L., Rosen, E. P., et al. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003570 · Cited by 3
Acceptability and Feasibility of Remote PrEP Visits for Adolescent Girls and Young Women in South Africa
Ndimande-Khoza, M. N., Velloza, J., Chauke, H., Mills, L., Poovan, N., Ndlovu, N., Concepcion, T. L., Hosek, S., Celum, C., & Delany‐Moretlwe, S. (2025) · AIDS and Behavior · doi:10.1007/s10461-025-04705-y · Cited by 3
Sharing of Investigational Drug Among Participants in the Voice Trial
Moodley, J., Naidoo, S., Moodley, J., & Gita Ramjee, H. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1414-x · Cited by 3
Mechanisms for Controlling HIV-1 Infection: A Gene Therapy Approach
Ognenovska, K., Klemm, V., Ledger, S., Turville, S. G., Symonds, G. P., Kelleher, A. D., & Ahlenstiel, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79669 · Cited by 3
Characteristics of women who use hormonal contraceptives and their population-level impacts on HIV infection in a cohort of South African women (2002–2016)
Wand, H. C., Morris, N., & Reddy, T. (2020) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2020.1831469 · Cited by 3
Imagined Futures and Unintended Consequences in the Making of PrEP: An Evidence-Making Intervention Perspective
Holt, M. (2021) · Social aspects of HIV · doi:10.1007/978-3-030-69819-5_18 · Cited by 3
Sexually Transmitted Infections
Koeppe, J. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-94632-6_6 · Cited by 3
Attitudes Among Men and Women Regarding Pre-exposure Prophylaxis to Prevent HIV Acquisition in an Urban HIV-Prevalent Setting in the United States
Koper, C., Dharan, N. J., Singh, B., Chew, D., Swaminathan, S., & Hodder, S. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv133.271 · Cited by 3
Where next with preexposure prophylaxis?
Nugent, D., & Gilson, R. J. C. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000340 · Cited by 3
Canadian guidelines on HIV pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP): Discussion beyond the guidelines and commentary on the role of infectious diseases specialists
Singh, A. E., Tan, D. H. S., Hull, M., Bogoch, I. I., MacPherson, P. A., Tremblay, C. L., & Shafran, S. D. (2018) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi.2018-0024 · Cited by 3
Non-adherence among women enrolled in a contraceptive vaginal ring use study in Kisumu, Kenya, 2014-2015
McLellan–Lemal, E., Gvetadze, R. J., Desai, M., Makanga, E. M., Pan, Y., Haaland, R. E., Holder, A. N., Mudhune, V., Williams, T., & Samandari, T. (2018) · Journal of Global Health Reports · doi:10.29392/joghr.2.e2018032 · Cited by 3
Pre‐exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children
Horgan, L., Blyth, C. C., Bowen, A. C., Nolan, D. A., & McLean‐Tooke, A. P. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50052 · Cited by 3
Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors
Janes, H., Brown, M. D., Glidden, D., Mayer, K., Buchbinder, S., McMahan, V. M., Schechter, M., Guanira, J., & Casapia, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222183 · Cited by 3
Impact of recurrent sexually transmitted infections on HIV seroconversion: Results from multi-state frailty models
Wand, H. C., Moodley, J., Reddy, T., & Naidoo, S. (2021) · International Journal of STD & AIDS · doi:10.1177/09564624211036587 · Cited by 3

Authors: Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
Affiliations: University of California, San Francisco (US)
Harborview Medical Center (US)
Family Health International 360 (US)
University of Zimbabwe (ZW)
Centre for the AIDS Programme of Research in South Africa (ZA)
University of Pittsburgh (US)
Johns Hopkins University (US)
South African Medical Research Council (ZA)
National Institutes of Health (US)
Eastern Virginia Medical School (US)
ORCID: Marrazzo, Jeanne M.
Richardson, Barbra A.
Gomez, Kailazarid
Mgodi, Nyaradzo
Nair, Gonasagrie
Nakabiito, Clemensia
Noguchi, Lisa
Hendrix, Craig W.
Dai, James Y.
Parikh, Urvi M.
Piper, Jeanna
Mâsse, Benoît
Rooney, James
Watts, Heather
Marzinke, Mark A.
Hillier, Sharon L.
McGowan, Ian M.
Chirenje, Z. Mike
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-05
Volume: 372
Issue: 6
Pages: 509-518
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1402269
PMC: PMC4341965
OpenAlex: W2044369525
Cited by: 1,296
References: 19
Citations by year: 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
FWCI: 147.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Funders: National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
MeSH terms: Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks